Trials / Completed
CompletedNCT01113580
A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population
A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2010/2011 Formulation of Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Years) and 'Older Adults' (Aged 60 Years or Older)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Seqirus · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CSL's 2010/2011 Formulation of Enzira® Vaccine | 45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0 |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2010-04-30
- Last updated
- 2017-11-21
- Results posted
- 2012-07-18
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01113580. Inclusion in this directory is not an endorsement.